High level of FHL2 exacerbates the outcome of non‐small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

High level of FHL2 exacerbates the outcome of non‐small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells

Published:2022-04-02 Issue:3 Volume:103 Page:90-101
ISSN:0959-9673
Container-title:International Journal of Experimental Pathology
language:en
Short-container-title:Int J Experimental Path

Author:

Li Na¹,Xu Ling²,Zhang Ji³,Liu Yongyu⁴^ORCID

Affiliation:

1. Department of Central Laboratory Shenyang Tenth People's HospitalShenyang Chest Hospital Liaoning China

2. Department of Interventional Pulmonary Diseases Anhui Chest Hospital Hefei China

3. Department of Cardiothoracic Surgery The Frist People's Hospital of Changde City Changde China

4. Department of Thoracic Surgery Shenyang Tenth People's HospitalShenyang Chest Hospital Liaoning China

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iep.12436

Reference34 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Encouraging long-term outcomes reported in patients with stage I non-small cell lung cancer treated with stereotactic ablative radiotherapy

3. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

4. The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy

5. Role of imaging in diagnosis, staging and follow-up of lung cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promotion of non-small cell lung cancer tumor growth by FHL2 via inducing angiogenesis and vascular permeability;Journal of Thoracic Disease;2024-02

2. FHL2 Determines Poor Outcomes and Responsiveness of Immunotherapy Plus Tyrosine Kinase Inhibition in Metastatic Renal Cell Carcinoma;Eurasian Journal of Medical Advances;2024

3. Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis;Scientific Reports;2023-10-02

4. Nanotechnology-empowered lung cancer therapy: From EMT role in cancer metastasis to application of nanoengineered structures for modulating growth and metastasis;Environmental Research;2023-09

5. Comprehensive pan-cancer analysis identifies FHL2 associated with poor prognosis in lung adenocarcinoma;Translational Cancer Research;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3